Drugs / qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04961541 | Sep → Dec 2021 | COVID-19 | Novavax | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04961541 ↗ |
| Known as | qNIV | “quadrivalent hemagglutinin (HA) nanoparticle influenza vaccine (qNIV)” NCT04961541 ↗ |
| Modality | Vaccine | “qNIV Nanoparticle Vaccine2” NCT04961541 ↗ |
| Route | Intramuscular | “Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2” NCT04961541 ↗ |